(Tonix) Pharmacokinetics of TNX-1700 in Non-Human Primates and Human FcRn/Serum Albumin Transgenic Mice

Abstract

TNX-1700 is a novel recombinant fusion molecule of human Trefoil Factor-2 (TFF2) protein and human serum albumin (HSA) that is being investigated as a potential therapeutic for gastric cancer. In syngeneic mouse models of gastric and colorectal cancer, TNX-1700 functions as a CXCR4 partial agonist that activates anti-tumor immunity in the tumor microenvironment by modulating myeloid cell trafficking to reduce tumor-induced granulopoiesis and accumulation of immunosuppressive neutrophils. TNX-1700 is engineered to extend plasma half-life, enhance systemic exposure, and improve cancer immunotherapy. The HSA domain in TNX-1700 provides a long circulatory half-life (>14 days) and multiple ligand-binding sites. Approved albumin linked drugs include detemir (Levemir®), liraglutide (Victoza®), and albiglutide (Eperzan®/Tanzeum®) for diabetes, and nanoparticle albumin bound paclitaxel (nab-paclitaxel) for cancer therapy. TNX-1700 represents a next-generation application of the albumin platform in immuno-oncology.